| Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using … S Boutin, V Monteilhet, P Veron, C Leborgne, O Benveniste, MF Montus, ... Human gene therapy 21 (6), 704-712, 2010 | 1130 | 2010 |
| Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial O Hermine, X Mariette, PL Tharaux, M Resche-Rigon, R Porcher, ... JAMA internal medicine 181 (1), 32-40, 2021 | 934 | 2021 |
| 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016 Y Allenbach, AL Mammen, O Benveniste, W Stenzel, A Amato, A Aussey, ... Neuromuscular disorders 28 (1), 87-99, 2018 | 522 | 2018 |
| Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies K Mariampillai, B Granger, D Amelin, M Guiguet, E Hachulla, F Maurier, ... JAMA neurology 75 (12), 1528-1537, 2018 | 440 | 2018 |
| Long-term observational study of sporadic inclusion body myositis O Benveniste, M Guiguet, J Freebody, O Dubourg, W Squier, ... Brain 134 (11), 3176-3184, 2011 | 345 | 2011 |
| Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin Y Allenbach, L Drouot, A Rigolet, JL Charuel, F Jouen, NB Romero, ... Medicine 93 (3), 150-157, 2014 | 333 | 2014 |
| Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity B Hervier, H Devilliers, R Stanciu, A Meyer, Y Uzunhan, A Masseau, ... Autoimmunity reviews 12 (2), 210-217, 2012 | 331 | 2012 |
| Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer M Touat, T Maisonobe, S Knauss, O Ben Hadj Salem, B Hervier, K Auré, ... Neurology 91 (10), e985-e994, 2018 | 330 | 2018 |
| Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial PL Tharaux, G Pialoux, A Pavot, X Mariette, O Hermine, M Resche-Rigon, ... The Lancet Respiratory Medicine 9 (3), 295-304, 2021 | 297 | 2021 |
| The EuroMyositis registry: an international collaborative tool to facilitate myositis research JB Lilleker, J Vencovsky, G Wang, LR Wedderburn, LP Diederichsen, ... Annals of the rheumatic diseases 77 (1), 30-39, 2018 | 280 | 2018 |
| High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody Y Allenbach, J Keraen, AM Bouvier, V Jooste, N Champtiaux, B Hervier, ... Brain 139 (8), 2131-2135, 2016 | 279 | 2016 |
| 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis … R Aggarwal, LG Rider, N Ruperto, N Bayat, B Erman, BM Feldman, ... Annals of the rheumatic diseases 76 (5), 792-801, 2017 | 276 | 2017 |
| 239th ENMC international workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018 AL Mammen, Y Allenbach, W Stenzel, O Benveniste, J De Bleecker, ... Neuromuscular Disorders 30 (1), 70-92, 2020 | 258 | 2020 |
| Correlation of anti–signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy O Benveniste, L Drouot, F Jouen, JL Charuel, C Bloch‐Queyrat, A Behin, ... Arthritis & Rheumatism 63 (7), 1961-1971, 2011 | 250 | 2011 |
| Immune-mediated necrotizing myopathy: clinical features and pathogenesis Y Allenbach, O Benveniste, W Stenzel, O Boyer Nature Reviews Rheumatology 16 (12), 689-701, 2020 | 249 | 2020 |
| JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis L Ladislau, X Suárez-Calvet, S Toquet, O Landon-Cardinal, D Amelin, ... Brain 141 (6), 1609-1621, 2018 | 221 | 2018 |
| A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8 V Monteilhet, S Saheb, S Boutin, C Leborgne, P Veron, MF Montus, ... Molecular Therapy 19 (11), 2084-2091, 2011 | 210 | 2011 |
| Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases Y Allenbach, Y Uzunhan, S Toquet, G Leroux, L Gallay, A Marquet, ... Neurology 95 (1), e70-e78, 2020 | 209 | 2020 |
| Interleukin‐21 modulates Th1 and Th17 responses in giant cell arteritis B Terrier, G Geri, W Chaara, Y Allenbach, M Rosenzwajg, ... Arthritis & Rheumatism 64 (6), 2001-2011, 2012 | 204 | 2012 |
| Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy NB Romero, S Braun, O Benveniste, F Leturcq, JY Hogrel, GE Morris, ... Human gene therapy 15 (11), 1065-1076, 2004 | 203 | 2004 |
